Laleh Jalilian1, Emma Essock-Burns1,2,
Susan M. Chang3, Soonmee Cha3,4, Sarah J. Nelson,
1,4
1Surbeck Laboratory of Advanced
Imaging, Department of Radiology, University of California, San Francisco,
San Francisco, CA, United States; 2UCSF/UCB Graduate Group in
Bioengineering, University of California, San Francisco, San Francisco, CA,
United States; 3Department of Neurological Surgery, University of
California, San Francisco, University of California, San Francisco, San
Francisco, CA, United States; 4Department of Radiology, University
of California, San Francisco, University of California, San Francisco, San
Francisco, CA, United States
Diffusion-weighted
Imaging (DWI) is an important adjunct to standard imaging in the management
of GBM patients receiving anti-angiogenic treatments. In this study, ADC
values were obtained for a) areas on preprogression scans that ultimately
progressed to new contrast-enhancement on progression scans (NEW_CEL), and b)
new FLAIR abnormality on preprogression scans with exclusion of areas of
contrast enhancement and areas that progress to new contrast-enhancement on
progression scans (T2ALL_M). Results
demonstrated increasing ADC values in NEW_CEL but no change in T2ALL_M in
scans prior to progression. Clinical
implications include interpreting new FLAIR abnormality as a consequence of
anti-angiogenic treatment alone.
Keywords